|
US2016030553A1
|
|
Allergen preparation
|
|
BR112014001292A2
|
|
dnak dosage
|
|
BR112013032398A2
|
|
method for the production of hydrolysed allergens
|
|
US2011111423A1
|
|
Demethylated and / or oxidized membrane DNA
|
|
US2010278880A1
|
|
Pharmaceutical formulation for allergen preparation
|
|
CN101528771A
|
|
Method for purification of DNAK
|
|
WO2008043832A1
|
|
Method for the purification of dnak
|
|
EP1872792A1
|
|
A method for the production of hydrolyzed allergen
|
|
US2006147459A1
|
|
Epitope composition for sublingual, buccal or enteric administration prepared by hydrolysis of antigenic structures with chymotrypsin
|
|
EP1641488A1
|
|
Epitope composition for enteric administration prepared by hydrolysis of antigenic structures with chymotrypsin
|
|
EP1625148A1
|
|
Peptide complex
|
|
WO2004036219A1
|
|
Demethylated and/or oxidized membrane dna and use thereof in the diagnostic of autoimmune diseases
|
|
EP1479689A1
|
|
Peptide complex
|
|
EP1501481A2
|
|
Dispersions of lipids for use as therapeutic and cosmetic agents and intracellular delivery vehicles
|
|
US6709672B2
|
|
Pharmaceutical or food composition for treating pathologies associated with graft rejection or an allergic or autoimmune reaction
|
|
US6613351B1
|
|
Compound capable of introducing at least one molecule into a cell
|
|
EP0902090A1
|
|
Compound capable of introducing at least one molecule into a cell.
|
|
EP0736002A1
|
|
Compound capable of introducing at least one molecule into a cell
|
